Clinical data management on-demand firm TrialStat has implemented Pure Storage’s FlashArray and Evergreen Storage subscriptions to expedite research in clinical trials. The solutions will also enable always-on data management services for TrialStat clients. Researchers in clinical trials gather and assess…
Synairgen concludes patient enrolment for Covid-19 trial
Synairgen has completed the recruitment of 610 subjects for its global Phase III SPRINTER trial (SG018) of inhaled interferon beta, SNG001, to treat hospitalised Covid-19 patients. The company’s double-blind, randomised, placebo-controlled Covid-19 trial is being conducted in 17 countries. Statistical…
Modulation Therapeutics obtains FDA approval to trial eye cancer drug
The US Food and Drug Administration (FDA) has approved investigational new drug application of Modulation Therapeutics to commence human trial of its drug, MTI-201, to treat uveal melanoma. Established in 2011, Modulation is a West Virginia University (WVU)-based start-up firm…
Biogen and Eisai report Phase III data for Aduhelm in Alzheimer’s disease
Biogen and Eisai have reported that their therapy, Aduhelm (aducanumab-avwa), substantially reduced plasma p-tau181 in two Phase III EMERGE and ENGAGE clinical trials. A monoclonal antibody, Aducanumab-avwa acts against amyloid-beta. The latest data from nearly 7,000 plasma samples obtained from…
FSSAI Tightens Rules for Foreign Companies Bringing Food Products in India
The FSSAI has announced a new regulatory framework for foreign facilities that transport food to India in order to ensure the safe import of food products. Foreign food manufacturing facilities that produce certain kinds of products for export to India…
Study shows HPV jab almost 90% effective at preventing cervical cancer
Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have…
Pfizer’s pill cuts COVID deaths and hospitalisations by 90%
An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection. The phase 3 trial found that Paxlovid – which combines new…
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. A phase 2 trial of iptacopan in patients with the rare…
Positive Results in Hand, AbbVie Eyes Potential Approval for Parkinson’s Treatment
AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease. The company announced that patients who received daily doses of the drug showed statistically significant…
A Diwali Gift For India: Bharat Biotech’s Covaxin Gets WHO Approval
The Technical Advisory Group of WHO, which met today, has recommended the Emergency Use Listing status for Bharat Biotech’s Covaxin – a decision that will ease international travel and the export of the indigenous vaccine. The World Health Organisation’s panel…
